Drug Trial Shows Reduced Abnormal Bone Formation in Those With Fibrodysplasia Ossificans Progressiva (IMAGE)

Vanderbilt University Medical Center

Drug Trial Shows Reduced Abnormal Bone Formation in Those With Fibrodysplasia Ossificans Progressiva

Caption

Cutline: Sharon Kantanie, center, participated in a phase 2 drug trial at Vanderbilt University Medical Center which showed reduced soft-tissue flare-ups and the prevention of new areas of abnormal bone formation. Others include, left to right, Emily Shardelow, clinical/translational research coordinator; Mary Kantanie, Sharon’s mother; Stan Kantanie, Sharon’s father; Margo Black, BSN, MSN, manager of Research Projects for Metabolic Bone Disorders at Vanderbilt; and Kathryn Dahir, MD, professor of Medicine in the Division of Endocrinology and Diabetes.

Credit

Photo by Erin O. Smith

Usage Restrictions

Vanderbilt University Medical Center

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.